New drug combo targets Hard-to-Treat pancreatic cancer
NCT ID NCT05257993
First seen Apr 16, 2026 · Last updated Jun 18, 2026 · Updated 8 times
Summary
This study tests a new drug called JPI-547 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to find the safest dose and see if the combination shrinks tumors. About 71 adults with locally advanced or metastatic pancreatic cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Samsung Medical Center
RECRUITINGSeoul, South Korea
Contact
-
Seoul National University Bundang Hospital
RECRUITINGGyeonggi-do, South Korea
Contact
-
Seoul national university hospital
RECRUITINGSeoul, South Korea
Contact
-
Severance Hospital
RECRUITINGSeoul, South Korea
Contact
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.